Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6745785 | 0.89 | KIF18A (0.55) | KIF18AKMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL15307418 | 0.84 | KIF18A (0.64) | KIF18AKMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL11786155 | 0.83 | VCAM1 (0.71) | KIF18AKMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL28539407 | 0.82 | KMT2A (0.77) | KIF18AKMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL9644188 | 0.81 | KIF18A (0.68) | KIF18AKMT2AMEN1POLBRAB9A | |
| SCHEMBL10384841 | 0.81 | KIF18A (0.68) | KIF18AKMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL11727447 | 0.81 | KIF18A (1.00) | KIF18AKMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL29355257 | 0.81 | KIF18A (1.00) | KIF18AKMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL15307422 | 0.81 | KIF18A (0.68) | KIF18AKMT2AMEN1POLBRAB9A | |
| SCHEMBL10040107 | 0.81 | KIF18A (0.68) | KIF18AKMT2ALMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014966-A1 | Bis-arylsulfones | JACOBSEN ERIC JON (US) | 2004-01-22 | — | — | US | disclosed |
| US-20030225065-A1 | Bis-arylsulfones | JACOBSEN ERIC JON (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030207866-A1 | Drugs useful for the treatment of diseases or disorders of the central nervous system. | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
| CN-1433407-A | Bis-aryl sulfones | PHARMACIA & UP JOHN CO (US) | 2003-07-30 | — | — | CN | disclosed |
| US-6586592-B2 | Labled isotopes of phenyl 4-(1,4-diazepin-1-yl)-2-amino phenyl sulfone derivatives used in nuclear magnetic resonance imaging and positron emission tomography | PHARMACIA & UPJOHN COMPANY | 2003-07-01 | — | — | US | disclosed |
| US-6579870-B2 | 5-(1,4-diazepan-1-yl)-2-((3 -fluorophenyl)sulfonyl)phenylamine for example; treatment of diseases or disorders of the central nervous system; modulation of serotonin (5-HT) activity | PHARMACIA & UPJOHN COMPANY | 2003-06-17 | — | — | US | disclosed |
| EP-1294701-A2 | BIS-ARYLSULFONES | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020115660-A1 | Bis -arylsulfones | PHARMACIA & UPJOHN COMPANY | 2002-08-22 | — | — | US | disclosed |
| US-20020037892-A1 | Bis-arylsulfones | PHARMACIA & UPJOHN COMPANY | 2002-03-28 | — | — | US | disclosed |
| WO-2001098279-A2 | BIS-ARYLSULFONES | PHARMACIA & UPJOHN COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207866-A1 | Drugs useful for the treatment of diseases or disorders of the central nervous system. | PMP22, NLN, INA | KIF18A 1960/4885KMT2A 3767/4885LMNA 2142/4885 |
| US-20020037892-A1 | Bis-arylsulfones | PMP22, ARSA, CLN6 | KIF18A 3988/4885KMT2A 3090/4885LMNA 3440/4885 |
| US-20020115660-A1 | Bis -arylsulfones | PMP22, ARSA, CLN6 | KIF18A 3988/4885KMT2A 3090/4885LMNA 3440/4885 |
| US-20030225065-A1 | Bis-arylsulfones | PMP22, ARSA, CLN6 | KIF18A 3988/4885KMT2A 3090/4885LMNA 3440/4885 |
| US-20040014966-A1 | Bis-arylsulfones | NPSR1, ARSA, SLC18A2 | KIF18A 4440/4885KMT2A 4280/4885LMNA 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.